OLSUTAMIG
UNII W5MSY5Q6CQ

Substance Identification & Data

This profile provides standardized clinical and technical data for Olsutamig, uniquely identified by the FDA Unique Ingredient Identifier (UNII) W5MSY5Q6CQ.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 3034664-43-9 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

W5MSY5Q6CQ

CAS Registry Number

3034664-43-9

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

OLSUTAMIG

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C185664

National Cancer Institute reference terminology for clinical and research data.

INN ID

13678

Sequential identifier assigned via the WHO International Nonproprietary Name program.

USAN ID

OP-183

Identifier assigned by the United States Adopted Names Council.

Substance Type

Olsutamig

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Olsutamig. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

Olsutamig

Common Names & Synonyms

H-gamma4 heavy chain anti-FOLH1 Homo sapiens (H) (1-450) [VH (Homo sapiens IGHV3-30*18 (94.9%) -(IGHD) -IGHJ1*01 (90.9%) L123>M (119), CDR-IMGT [8.8.17] (26-33.51-58.97-113)) (1-124) -Homo sapiens IGHG4*01, nG4m(a) CH2 L92, 12-G4v5 h P10, 1-G4v50 CH2 delE1.4, P1.3, V1.2, A1.1(CH1 (125-222), hinge 1-12 S10>P (232) (223-234), CH2 E1.4>del, L1.3>P (237), L1.2>V (238), G1.1>A (239), L92 (312) (235-343), CH3 (344-448), CHS (449-450)) (125-450)], (138-215')-disulfide with common L-kappa light chain Homo sapiens (L') (1'-215') [V-KAPPA (Homo sapiens IGKV1-39*01 (100%) -IGKJ5*01 (100%), CDR-IMGT[6.3.10] (27'-32'.50'-52'.89'-98')) (1'-108') -Homo sapiens IGKC*01 (100%) Km3 A45.1, V101 (C-KAPPA A45.1 (154'), V101 (192') (109'-215')]; H-gamma4 heavy chain anti-CD3 Homo sapiens (H'') (1''-450'') [VH (Homo sapiens IGHV3-9*01 (99.0%) -(IGHD) -IGHJ6*01 (94.7%), CDR-IMGT [8.8.17] (26''-33''.51''-58''.97''-113'')) (1''-124'') -Homo sapiens IGHG4*01, nG4m(a) CH2 L92, 12-G4v5 h P10, 1-G4v50 CH2 delE1.4, P1.3, V1.2, A1.1, 10-G4v8 CH3 R115, F116, P125(CH1 (125''-222''), hinge 1-12 S10>P (232'') (223''-234''), CH2 E1.4>del, L1.3>P (237''), L1.2>V (238''), G1.1>A (239''), L92 (312'') (235''-343''), CH3 H115>R (438), Y116>F (439), L125>P (448) (344''-448''), CHS (449''-450'')) (125''-450'')], (138''-215''')-disulfide with common L-kappa light chain Homo sapiens (L''') (1'''-215''') [V-KAPPA (Homo sapiens IGKV1-39*01 (100%) -IGKJ5*01 (100%), CDR-IMGT [6.3.10] (27'''-32'''.50'''-52'''.89'''-98''')) (1'''-108''') -Homo sapiens IGKC*01 (100%) Km3 A45.1, V101 (C-KAPPA A45.1 (154'''), V101 (192''') (109'''-215''')], dimer (230-230'':233-233'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, cell line CHO-K1, glycoform alfa

Immunoglobulin G4 [232-proline,237-proline,238-valine,239-alanine,de-240-glycine], anti-(human prostate-specific membrane antigen) (human monoclonal REGN4336 γ4-chain), disulfide with human monoclonal REGN4336 κ-chain, (230→230′),(233→233′)-bis(disulfide) with immunoglobulin G4 [232-proline,237-proline,238-valine,239-alanine,de-240-glycine,439-arginine,440-phenylalanine,449-proline] anti-(human CD3 antigen ε-chain) (human monoclonal REGN4336 γ4-chain) disulfide with human monoclonal REGN4336 κ-chain

OLSUTAMIG [USAN]

immunoglobulin (H-gamma4_L-kappa)_( H-gamma4_L-kappa), anti-[Homo sapiens FOLH1 (folate hydrolase, prostate specific membrane antigen, PSMA)] and anti-[Homo sapiens CD3E (CD3 epsilon, Leu-4)], Homo sapiens monoclonal antibody, bispecific, bivalen (olsutamig)

olsutamig [INN]